ICU Medical, Inc. (NASDAQ:ICUI) Stake Lowered by Boston Trust Walden Corp

Boston Trust Walden Corp trimmed its stake in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 2.8% during the fourth quarter, Holdings Channel reports. The firm owned 317,246 shares of the medical instruments supplier’s stock after selling 9,056 shares during the period. Boston Trust Walden Corp’s holdings in ICU Medical were worth $49,227,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in ICUI. Creative Planning increased its holdings in shares of ICU Medical by 75.5% during the second quarter. Creative Planning now owns 3,906 shares of the medical instruments supplier’s stock valued at $464,000 after purchasing an additional 1,680 shares during the period. Truist Financial Corp acquired a new position in ICU Medical during the 2nd quarter valued at about $310,000. GAMMA Investing LLC raised its position in shares of ICU Medical by 83.6% during the 3rd quarter. GAMMA Investing LLC now owns 571 shares of the medical instruments supplier’s stock worth $104,000 after buying an additional 260 shares in the last quarter. Diversified Trust Co acquired a new stake in shares of ICU Medical in the 3rd quarter worth approximately $455,000. Finally, Hexagon Capital Partners LLC boosted its holdings in shares of ICU Medical by 162.7% in the third quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 122 shares in the last quarter. Institutional investors own 96.10% of the company’s stock.

Insiders Place Their Bets

In other ICU Medical news, Director David C. Greenberg sold 972 shares of ICU Medical stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $158.11, for a total transaction of $153,682.92. Following the sale, the director now directly owns 5,037 shares of the company’s stock, valued at approximately $796,400.07. The trade was a 16.18 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Christian B. Voigtlander sold 1,962 shares of the stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $169.08, for a total value of $331,734.96. The disclosure for this sale can be found here. Insiders sold a total of 17,737 shares of company stock valued at $2,879,752 in the last quarter. Insiders own 6.70% of the company’s stock.

ICU Medical Stock Performance

Shares of ICUI opened at $158.69 on Tuesday. ICU Medical, Inc. has a 12 month low of $86.80 and a 12 month high of $196.26. The company’s fifty day moving average is $160.80 and its 200-day moving average is $162.77. The company has a quick ratio of 1.03, a current ratio of 2.29 and a debt-to-equity ratio of 0.75. The firm has a market cap of $3.88 billion, a price-to-earnings ratio of -34.72 and a beta of 0.63.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ICUI. Jefferies Financial Group raised ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price objective on the stock in a research note on Wednesday, December 11th. StockNews.com raised shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Wednesday, November 20th. Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a research note on Wednesday, November 13th. Finally, KeyCorp boosted their target price on shares of ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a report on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $199.67.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.